Welcome to our dedicated page for Lexicon Pharmaceuticals SEC filings (Ticker: LXRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) SEC filings page on Stock Titan provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. These filings offer detailed information on Lexicon’s biopharmaceutical operations, financial condition, capital-raising activities and risks associated with its pipeline in heart failure, hypertrophic cardiomyopathy, neuropathic pain, obesity, diabetes and related indications.
Investors can review current reports on Form 8-K, where Lexicon discloses material events such as quarterly financial results, at-the-market equity offering arrangements, Nasdaq listing status updates and key business developments. For example, recent 8-K filings describe an Open Market Sale Agreement with Jefferies LLC, legal opinions related to potential share sales, and communications regarding compliance with Nasdaq’s minimum bid price requirement and transfer to The Nasdaq Capital Market.
In addition to 8-Ks, users can locate Lexicon’s annual reports on Form 10-K and quarterly reports on Form 10-Q (when available through EDGAR), which typically contain audited financial statements, management’s discussion and analysis, detailed descriptions of products such as sotagliflozin (INPEFA®), pilavapadin (LX9211) and LX9851, as well as information on licensing agreements with partners like Viatris and Novo Nordisk. Proxy materials and other filings may address executive compensation, governance and shareholder matters.
Stock Titan enhances these documents with AI-powered summaries that highlight key points from lengthy reports, helping users quickly understand major changes in revenue sources, R&D priorities, collaboration structures, risk factors and capital structure. Real-time updates from EDGAR ensure that new Lexicon filings, including any Form 4 insider transaction reports, become accessible promptly, while AI-generated overviews make complex regulatory language more approachable for both individual and institutional investors.
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company focused on small‑molecule drugs for cardiovascular, metabolic and neuropathic diseases, built on internal target discovery from about 5,000 genes. The company devotes most resources to sotagliflozin, pilavapadin, LX9851 and commercialization of INPEFA.
INPEFA (sotagliflozin) is approved in the U.S. to reduce cardiovascular death and heart‑failure events in adults with heart failure or type 2 diabetes, chronic kidney disease and other cardiovascular risk factors, and is sold mainly through major wholesalers and a mail‑order pharmacy. Sotagliflozin is also in the SONATA‑HCM Phase 3 trial for hypertrophic cardiomyopathy and is being pursued as ZYNQUISTA for type 1 diabetes after FDA complete response letters, with a potential NDA resubmission supported by the STENO1 study.
Pilavapadin has shown evidence of effect in multiple Phase 2 neuropathic pain trials and holds FDA Fast Track designation for diabetic peripheral neuropathic pain, with Phase 3 advancement contingent on third‑party collaboration. LX9851 for obesity is licensed exclusively to Novo Nordisk, which paid a
Lexicon Pharmaceuticals reported 2025 results showing higher revenue and a sharply reduced loss while advancing its pipeline. Total revenues were $49.8 million in 2025 versus $31.1 million in 2024, largely driven by $45 million of licensing revenue from a Novo Nordisk agreement and $4.6 million of INPEFA net sales.
Net loss narrowed to $50.3 million, or $0.14 per share, from $200.4 million, or $0.63 per share, helped by major cost reductions. Research and development expenses fell to $61.1 million from $84.5 million, and selling, general and administrative expenses dropped to $37.3 million from $143.1 million, reflecting a strategic repositioning and reduced INPEFA marketing.
As of December 31, 2025, cash, investments and restricted cash totaled $125.2 million, and in February 2026 the company added approximately $96.7 million of net equity proceeds plus a $10 million milestone payment from Novo Nordisk. Key programs progressed, including SONATA-HCM Phase 3 enrollment surpassing 50%, planned 2026 NDA resubmission for ZYNQUISTA in type 1 diabetes, and Phase 3 readiness for pilavapadin in diabetic neuropathic pain.
Lexicon Pharmaceuticals senior vice president Wendy McDermott reported multiple equity award transactions involving restricted stock units and common stock. On February 28, 2026, she exercised or converted several blocks of restricted stock units into common shares at a stated price of $0.00 per share, including a tranche of 144,393 restricted stock units that became common stock. Each restricted stock unit represents the right to receive one share of common stock, and the units vest in three equal annual installments each February 28 following the grant year.
On the same date, 68,107 common shares were withheld at $1.47 per share to satisfy tax withholding obligations, a non‑market transaction classified as a tax‑withholding disposition. After these transactions, McDermott continued to hold common stock directly, reflecting equity compensation rather than open‑market trading.
LEXICON PHARMACEUTICALS, INC. senior vice president Rachel Yap Martens reported equity compensation activity involving restricted stock units and common shares. On February 28, 2026, she exercised 67,090 restricted stock units, converting them into 67,090 shares of common stock at a price of $0.00 per share.
In a related tax event on the same date, 35,826 common shares were disposed of at $1.47 per share to satisfy tax withholding obligations, as described in the footnotes. After these transactions, she held 31,264 shares of common stock and 134,180 restricted stock units directly. Each restricted stock unit represents the right to receive one share of common stock and vests in three equal annual installments each February 28 following the grant year.
LEXICON PHARMACEUTICALS, INC. Senior Vice President and Chief Medical Officer Craig B. Granowitz reported multiple equity award transactions involving restricted stock units and common stock on February 28, 2026.
He exercised or converted restricted stock units into common shares in three separate transactions of 35,790, 74,226, and 202,260 restricted stock units, each at a stated price of $0.00 per unit. Each restricted stock unit represents a contingent right to receive one share of common stock, and these units vest in three equal annual installments on February 28 of each of the three years following the year of grant.
Corresponding non-derivative entries show acquisitions of common stock in matching amounts of 35,790, 74,226, and 202,260 shares, reflecting the settlement of those restricted stock units. A separate transaction disposed of 109,098 shares of common stock at $1.47 per share through withholding of a portion of the issued shares by the company to satisfy the reporting person’s tax withholding obligations. After these transactions, the reporting person directly owned 323,430 shares of common stock.
LEXICON PHARMACEUTICALS, INC. senior vice president of Discovery, Suma Gopinathan, reported multiple equity compensation transactions. On February 28, 2026, she acquired common stock through the exercise and conversion of restricted stock units in blocks of 14,000, 20,310 and 65,640 shares, each at a conversion price of
LEXICON PHARMACEUTICALS, INC. senior vice president Lisa DeFrancesco reported equity award activity on common stock. On February 28, 2026, she acquired shares through the exercise and conversion of restricted stock units, including 24,674 and 128,190 units, each representing a right to one common share. A separate transaction disposed of 74,572 common shares at $1.47 per share to satisfy tax withholding obligations, leaving her with directly owned common shares as reported in the filing.
LEXICON PHARMACEUTICALS SVP and General Counsel Brian T. Crum reported multiple exercises of restricted stock units into common stock on February 28, 2026. These were non-cash conversions at $0.00 per share, increasing his directly held common shares. The company also withheld 105,019 common shares at $1.47 per share to cover tax obligations related to the equity awards.
Lexicon Pharmaceuticals SVP & CFO Scott M. Coiante reported equity award activity. On February 28, he acquired 160,237 shares of common stock through the exercise of restricted stock units at no cost, while 54,881 shares were withheld by the company to cover tax obligations. Following these transactions, he directly owns 105,356 shares of common stock and 320,473 restricted stock units, each representing the right to receive one share as they vest over time.
LEXICON PHARMACEUTICALS, INC. Chief Executive Officer Michael Exton reported equity award activity involving restricted stock units and common stock on February 28, 2026. He exercised or converted 503,263 restricted stock units, receiving an equivalent number of common shares at a stated price of $0.00 per share.
In a related tax-withholding disposition, 204,831 common shares were withheld by the company at $1.47 per share to satisfy withholding obligations. Following these transactions, Exton directly held 1,006,527 restricted stock units and 298,432 common shares. The footnotes clarify that each restricted stock unit converts into one share and that vesting occurs in three equal annual installments after grant.